Search Results

You are looking at 1 - 10 of 59 items for :

  • Refine by Access: All content x
Clear All
Open access

Thozhukat Sathyapalan, Anne-Marie Coady, Eric S Kilpatrick, and Stephen L Atkin

Background Statin (HMG-CoA reductase) treatment is effective in the primary and secondary prevention of cardiovascular disease (CVD) events ( 1 , 2 ) and is generally safe and well tolerated ( 2 ). In the West of Scotland Coronary Study

Open access

Melody Lok-Yi Chan, Sammy Wing-Ming Shiu, Ching-Lung Cheung, Anskar Yu-Hung Leung, and Kathryn Choon-Beng Tan

increases the expression of genes that promote cholesterol efflux ( 9 ). In addition to regulation by LXR, it has recently been suggested that statins may potentially influence IDOL expression in vitro ( 10 ). Statins are most widely used in lipid

Open access

Lang Qin, Xiaoming Zhu, Xiaoxia Liu, Meifang Zeng, Ran Tao, Yan Zhuang, Yiting Zhou, Zhaoyun Zhang, Yehong Yang, Yiming Li, Yongfei Wang, and Hongying Ye

associated with hypercortisolism. Intensive cholesterol reduction may be beneficial in the treatment of patients with hypertension and normal lipid levels, through a reduction in large artery stiffness. Ferrier found an additional statin therapy led to a

Open access

Anastasia P Athanasoulia-Kaspar, Matthias K Auer, Günter K Stalla, and Mira Jakovcevski

.a. Waist-to-hip-ratio 67 48 1.03 1.08 n.a. n.a. n.a. n.a. n.a. Hypercholesterolemia/statin use 31 (27.0) 0 n.a. n.a. 14 (13.2) 2 n.a. n.a. 0.016 Triglycerides (mg/dL) 98 17 141.04 80.1 n.a. n

Open access

Selina Mäkinen, Neeta Datta, Yen H Nguyen, Petro Kyrylenko, Markku Laakso, and Heikki A Koistinen

Introduction HMG-CoA reductase inhibitors, statins, lower cholesterol levels by inhibiting mevalonate formation, the rate-limiting step in the cholesterol biosynthesis ( 1 ). These drugs are widely used and effective in primary ( 2 , 3 ) and

Open access

Kristin Godang, Karolina Lundstam, Charlotte Mollerup, Stine Lyngvi Fougner, Ylva Pernow, Jörgen Nordenström, Thord Rosén, Svante Jansson, Mikael Hellström, Jens Bollerslev, Ansgar Heck, and the SIPH Study Group

statins in study period. The decrease in the OBS group was not significant ( P  = 0.079), and there was no difference between groups ( P  = 0.12). Table 2 Metabolic parameters, change over time and between the two randomization groups over

Open access

Josephina G Kuiper, Aline C Fenneman, Anne H van der Spek, Elena Rampanelli, Max Nieuwdorp, Myrthe P P van Herk-Sukel, Valery E P P Lemmens, Ernst J Kuipers, Ron M C Herings, and Eric Fliers

that potentially decrease the risk of CRC including use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), statins, antidiabetics (both oral antidiabetics and insulin), hormone replacement therapy, and oral contraceptives. Non-users of

Open access

Simon Chang, Christian Fynbo Christiansen, Anders Bojesen, Svend Juul, Anna-Marie B Münster, and Claus H Gravholt

of disease-specific medications were assessed to indirectly evaluate the incidence and timing of comorbidities, for example, insulin or oral antidiabetics as an indicator for diabetes and statins for hypercholesterolemia. Results from clinical

Open access

Trevor Lewis, Eva Zeisig, and Jamie E Gaida

and associated metabolic conditions, such as insulin resistance ( 5 ), diabetes ( 6 ), hypercholesterolaemia ( 7 ), statins ( 8 ), abdominal fat ( 9 ), the sympathetic nervous system ( 10 , 11 ), and corticosteroid use ( 12 ). Glucocorticoids are a

Open access

Yutong Zou, Lijun Zhao, Junlin Zhang, Yiting Wang, Yucheng Wu, Honghong Ren, Tingli Wang, Rui Zhang, Jiali Wang, Yuancheng Zhao, Chunmei Qin, Huan Xu, Lin Li, Zhonglin Chai, Mark E Cooper, Nanwei Tong, and Fang Liu

(ARB), statins and antihyperuricemic drug. The trajectories of eGFR decline and SUA change were evaluated using a simple linear model. Moreover, hyperuricemia was defined as SUA higher than 420 μmol/L in men and 360 μmol/L in women. Renal biopsy